BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 24934899)

  • 1. Induced regulatory T cells in inhibitory microenvironments created by cancer.
    Whiteside TL
    Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.
    Chaudhary B; Abd Al Samid M; al-Ramadi BK; Elkord E
    Expert Opin Biol Ther; 2014 Jul; 14(7):931-45. PubMed ID: 24661020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of heterogeneous regulatory T cells in the tumor microenvironment.
    Wei T; Zhong W; Li Q
    Pharmacol Res; 2020 Mar; 153():104659. PubMed ID: 31982490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dual Role of Treg in Cancer.
    Frydrychowicz M; Boruczkowski M; Kolecka-Bednarczyk A; Dworacki G
    Scand J Immunol; 2017 Dec; 86(6):436-443. PubMed ID: 28941312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment.
    Scott EN; Gocher AM; Workman CJ; Vignali DAA
    Front Immunol; 2021; 12():702726. PubMed ID: 34177968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T Cells in the Tumor Microenvironment.
    Dadey RE; Workman CJ; Vignali DAA
    Adv Exp Med Biol; 2020; 1273():105-134. PubMed ID: 33119878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?
    Whiteside TL
    Cancer Immunol Immunother; 2014 Jan; 63(1):67-72. PubMed ID: 24213679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirement of Treg-intrinsic CTLA4/PKCĪ· signaling pathway for suppressing tumor immunity.
    Pedros C; Canonigo-Balancio AJ; Kong KF; Altman A
    JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treg programming and therapeutic reprogramming in cancer.
    Moreno Ayala MA; Li Z; DuPage M
    Immunology; 2019 Jul; 157(3):198-209. PubMed ID: 30866047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses.
    Hoelzinger DB; Smith SE; Mirza N; Dominguez AL; Manrique SZ; Lustgarten J
    J Immunol; 2010 Jun; 184(12):6833-42. PubMed ID: 20483762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.
    Dwarakanath BS; Farooque A; Gupta S
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e21105. PubMed ID: 32729245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.
    Whiteside TL
    Expert Opin Ther Targets; 2018 Apr; 22(4):353-363. PubMed ID: 29532697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.
    Munn DH; Sharma MD; Johnson TS
    Cancer Res; 2018 Sep; 78(18):5191-5199. PubMed ID: 30181177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.